SCHEMBL3917033

SCHEMBL3917033

COC(=O)C1NC(=O)c2ccccc2-c2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.44
▸ CYP1A2 P05177 1/20 0.43
▸ HSD17B10 Q99714 2/20 0.41
▸ KMT2A Q03164 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ TNKS2 Q9H2K2 2/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ PBRM1 Q86U86 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ MAPT P10636 1/20 0.38
▸ ITGA4 P13612 1/20 0.38
▸ HDAC3 O15379 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC7 Q8WUI4 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ HDAC9 Q9UKV0 1/20 0.38
▸ HDAC5 Q9UQL6 1/20 0.38
▸ NCOR2 Q9Y618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14398778 0.79 HSD17B10 (0.51) POLBCYP1A2HSD17B10TNKS2PARP1
SCHEMBL12185431 0.77 CYP1A2 (0.62) POLBCYP1A2HSD17B10KMT2AMEN1
SCHEMBL30883118 0.76 PARP1 (0.38) PARP1ALDH1A1
SCHEMBL2597979 0.75 CYP1A2 (0.49) CYP1A2HSD17B10KMT2ATNKS2PARP1
SCHEMBL13135997 0.75 HSD17B10 (0.50) POLBCYP1A2HSD17B10TNKS2PARP1
SCHEMBL5187013 0.74 ALDH1A1 (0.37) POLBCYP1A2HSD17B10KMT2AGAA
SCHEMBL28053935 0.74 PBRM1 (0.41) POLBHSD17B10TNKS2PBRM1GAA
SCHEMBL2597846 0.73 HSD17B10 (0.51) CYP1A2HSD17B10KMT2ATNKS2PARP1
SCHEMBL106257 0.72 HDAC4 (0.57) POLBKMT2AMEN1GAAALDH1A1
SCHEMBL3751967 0.71 HSD17B10 (0.58) CYP1A2HSD17B10KMT2ATNKS2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 — — US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 — — US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 — — EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC POLB 2399/4885CYP1A2 2366/4885HSD17B10 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback